Burning Rock Biotech (BNR) Stock: Buy, Sell, or Hold?
BNR - Burning Rock Biotech Limited American Depositary Shares
$15.00
-0.49 (-3.16%)
âŧ
5d:
-5.21%
30d:
+22.15%
90d:
+40.71%
WAIT
LOW Confidence
Analysis Updated: Oct 12, 2026 12:00 AM ET
Earnings: Nov 19, 2026
Get Alerted When BNR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: BNR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: BNR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: BNR is currently trading at $15.00, which is considered fair relative to its 30-day fair value range of $12.20 to $17.06.
Technical Outlook: Technically, BNR is in a uptrend. Immediate support is located at $14.41, while resistance sits at $19.45. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: BNR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.03. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BNR is in a uptrend. Immediate support is located at $14.41, while resistance sits at $19.45. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: BNR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. However, the stock is trading significantly above the average Wall Street target of $4.03. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$12.20 -
$17.06
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
34.2%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BEARISH: Trading 73.1% above Wall St target ($4.03)
- WARNING: Composite score 36/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$12.20 -
$17.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$14.41
Resistance Level
$19.45
Current Trend
Uptrend
Technical data as of
Oct 12, 2026
Fundamental Context
Wall Street Target
$4.03
(-73.1%)
Revenue Growth (YoY)
-9.3%
Profit Margin
-13.6%
Share & Embed Analysis
Last updated: October 12, 2026 9:16 PM ET
Data refreshes hourly during market hours. Next update: 10:16 PM
Data refreshes hourly during market hours. Next update: 10:16 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BNR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
27 analysts |
$677 | 54 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$200 | 44 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$241 | 53 HOLD |
|
IQV
IQVIA Holdings Inc |
STRONG BUY
22 analysts |
$295 | 58 HOLD |
